Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12778-12790

  Wu, Wei Ding ^a   Hu, Zhi Ming ^a   Shang, Min Jie ^a   Zhao, Da Jian ^a   Zhang, Cheng Wu ^a   Hong, De Fei ^a   Huang, Dong Sheng ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

AMPK; Cordycepin; HIF 1 ; MTORC1 and chemo sensitization; Multiple drug resistant (MDR); The gallbladder cancer

Indexed keywords

CASPASE 3; CORDYCEPIN; FLUOROURACIL; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; DEOXYADENOSINE DERIVATIVE; DEOXYCYTIDINE; HIF1A PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GALLBLADDER CANCER; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MTT ASSAY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GALLBLADDER TUMOR; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DEOXYADENOSINES; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84904512073     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712778     Document Type: Article

References (49)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
2. Reid, K. M.; Ramos-De la Medina, A.; Donohue, J. H. Diagnosis and surgical management of gallbladder cancer: A review. J. Gastrointest. Surg. 2007, 11, 671-681.
3. Bartlett, D. L.; Fong, Y.; Fortner, J. G.; Brennan, M. F.; Blumgart, L. H. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann. Surg. 1996, 224, 639-646.
4. Lazcano-Ponce, E. C.; Miquel, J. F.; Munoz, N.; Herrero, R.; Ferrecio, C.; Wistuba, I. I.; Alonso de Ruiz, P.; Aristi Urista, G.; Nervi, F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J. Clin. 2001, 51, 349-364.
5. Horgan, A. M.; Amir, E.; Walter, T.; Knox, J. J. Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J. Clin. Oncol. 2012, 30, 1934-1940.
6. Bonet Beltran, M.; Allal, A. S.; Gich, I.; Sole, J. M.; Carrio, I. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat. Rev. 2012, 38, 111-119.
7. Shi, P.; Huang, Z.; Tan, X.; Chen, G. Proteomic detection of changes in protein expression induced by cordycepin in human hepatocellular carcinoma BEL-7402 cells. Methods Find. Exp. Clin. Pharmacol. 2008, 30, 347-353.
8. Chang, W.; Lim, S.; Song, H.; Song, B. W.; Kim, H. J.; Cha, M. J.; Sung, J. M.; Kim, T. W.; Hwang, K. C. Cordycepin inhibits vascular smooth muscle cell proliferation. Eur. J. Pharmacol. 2008, 597, 64-69.
9. Ng, T. B.; Wang, H. X. Pharmacological actions of Cordyceps, a prized folk medicine. J. Pharm. Pharmacol. 2005, 57, 1509-1519.
10. Wong, Y. Y.; Moon, A.; Duffin, R.; Barthet-Barateig, A.; Meijer, H. A.; Clemens, M. J.; de Moor, C. H. Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J. Biol. Chem. 2010, 285, 2610-2621.
11. Tuli, H. S.; Sharma, A. K.; Sandhu, S. S.; Kashyap, D. Cordycepin: A bioactive metabolite with therapeutic potential. Life Sci. 2013, 93, 863-869.
12. Zhang, D. W.; Wang, Z. L.; Qi, W.; Lei, W.; Zhao, G. Y. Cordycepin (3'-deoxyadenosine) down-regulates the proinflammatory cytokines in inflammation-induced osteoporosis model. Inflammation 2014, 37, 1044-1049.
13. Wang, Z.; Wang, X.; Qu, K.; Zhu, P.; Guo, N.; Zhang, R.; Abliz, Z.; Yu, H.; Zhu, H. Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation. Chem. Biol. Drug Des. 2010, 76, 340-344.
14. Hardie, D. G. AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8, 774-785.
15. Wang, S.; Song, P.; Zou, M. H. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin. Sci. 2012, 122, 555-573.
16. Luo, Z.; Saha, A. K.; Xiang, X.; Ruderman, N. B. AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci. 2005, 26, 69-76.
17. Chen, M. B.; Shen, W. X.; Yang, Y.; Wu, X. Y.; Gu, J. H.; Lu, P. H. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J. Cell Physiol. 2011, 226, 1915-1925.
18. Chen, M. B.; Zhang, Y.; Wei, M. X.; Shen, W.; Wu, X. Y.; Yao, C.; Lu, P. H. Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells. Cell Signal. 2013, 25, 1993-2002.
19. Rocha, G. Z.; Dias, M. M.; Ropelle, E. R.; Osorio-Costa, F.; Rossato, F. A.; Vercesi, A. E.; Saad, M. J.; Carvalheira, J. B. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 2011, 17, 3993-4005.
20. Sun, H.; Yu, T.; Li, J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition. Cancer Lett. 2011, 310, 118-128.
21. Zhang, W. B.; Wang, Z.; Shu, F.; Jin, Y. H.; Liu, H. Y.; Wang, Q. J.; Yang, Y. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 2010, 285, 40461-40471.
22. Chen, M. B.; Wu, X. Y.; Gu, J. H.; Guo, Q. T.; Shen, W. X.; Lu, P. H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys. 2011, 60, 311-322.
23. Ji, C.; Yang, B.; Yang, Y. L.; He, S. H.; Miao, D. S.; He, L.; Bi, Z. G. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29, 6557-6568.
24. Zheng, Q. Y.; Jin, F. S.; Yao, C.; Zhang, T.; Zhang, G. H.; Ai, X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem. Biophys. Res. Commun. 2012, 419, 741-747.
25. Hwang, J. T.; Ha, J.; Park, I. J.; Lee, S. K.; Baik, H. W.; Kim, Y. M.; Park, O. J. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett. 2007, 247, 115-121.
26. Lee, Y. K.; Hwang, J. T.; Kwon, D. Y.; Surh, Y. J.; Park, O. J. Induction of apoptosis by quercetin is mediated through AMPKalpha1/ASK1/p38 pathway. Cancer Lett. 2010, 292, 228-236.
27. Chen, L.; Xu, B.; Liu, L.; Luo, Y.; Yin, J.; Zhou, H.; Chen, W.; Shen, T.; Han, X.; Huang, S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab. Investig. 2010, 90, 762-773.
28. 2-induced apoptosis in human skin keratinocytes. J. Biol. Chem. 2008, 283, 28897-28908.
29. Guo, P.; Kai, Q.; Gao, J.; Lian, Z. Q.; Wu, C. M.; Wu, C. A.; Zhu, H. B. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase. J. Pharmacol. Sci. 2010, 113, 395-403.
30. Inoki, K.; Zhu, T.; Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115, 577-590.
31. Stavrovskaya, A. A.; Stromskaya, T. P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008, 73, 592-604.
32. Wang, B. L.; Zhai, H. Y.; Chen, B. Y.; Zhai, S. P.; Yang, H. Y.; Chen, X. P.; Zhao, W. T.; Meng, L. Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis. Int. 2004, 3, 296-299.
33. Dancey, J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7, 209-219.
34. Caldow Pilgrim, C. H.; Groeschl, R. T.; Quebbeman, E. J.; Gamblin, T. C. Recent advances in systemic therapies and radiotherapy for gallbladder cancer. Surg. Oncol. 2013, 22, 61-67.
35. McNamara, M. G.; Metran-Nascente, C.; Knox, J. J. State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr. Opin. Oncol. 2013, 25, 425-431.
36. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9-22.
37. Efeyan, A.; Sabatini, D. M. mTOR and cancer: Many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22, 169-176.
38. Laplante, M.; Sabatini, D. M. mTOR signaling in growth control and disease. Cell 2012, 149, 274-293.
39. Sabatini, D. M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 2006, 6, 729-734.
40. Sun, W.; Shen, Z. Y.; Zhang, H.; Fan, Y. Z.; Zhang, W. Z.; Zhang, J. T.; Lu, X. S.; Ye, C. Overexpression of HIF-1alpha in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol. Rep. 2012, 27, 1990-2002.
41. Batmunkh, E.; Shimada, M.; Morine, Y.; Imura, S.; Kanemura, H.; Arakawa, Y.; Hanaoka, J.; Kanamoto, M.; Sugimoto, K.; Nishi, M. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int. J. Clin. Oncol. 2010, 15, 59-64.
42. Gwinn, D. M.; Shackelford, D. B.; Egan, D. F.; Mihaylova, M. M.; Mery, A.; Vasquez, D. S.; Turk, B. E.; Shaw, R. J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30, 214-226.
43. Yang, X. H.; Zheng, X.; Cao, J. G.; Xiang, H. L.; Liu, F.; Lv, Y. 8-Bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J. Gastroenterol. 2012, 16, 3385-3393.
44. Yap, T. A.; Yan, L.; Patnaik, A.; Fearen, I.; Olmos, D.; Papadopoulos, K.; Baird, R. D.; Delgado, L.; Taylor, A.; Lupinacci, L.; et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29, 4688-4695.
45. Brunn, G. J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J. C., Jr.; Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996, 15, 5256-5267.
46. Wang, W.; Sun, Y. P.; Huang, X. Z.; He, M.; Chen, Y. Y.; Shi, G. Y.; Li, H.; Yi, J.; Wang, J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem. Pharmacol. 2010, 79, 1134-1140.
47. Lee, S. J.; Moon, G. S.; Jung, K. H.; Kim, W. J.; Moon, S. K. c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells. Food Chem. Toxicol. 2010, 48, 277-283.
48. Ruma, I. M.; Putranto, E. W.; Kondo, E.; Watanabe, R.; Saito, K.; Inoue, Y.; Yamamoto, K.; Nakata, S.; Kaihata, M.; Murata, H.; et al. Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells. Int. J. Oncol. 2014, 45, 209-218.
49. Wu, W. C.; Hsiao, J. R.; Lian, Y. Y.; Lin, C. Y.; Huang, B. M. The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother. Pharmacol. 2007, 60, 103-111.